相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Olorofim Susceptibility Testing of 1,423 Danish Mold Isolates Obtained in 2018-2019 Confirms Uniform and Broad-Spectrum Activity
Karen Marie Thyssen Astvad et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial
George R. Thompson et al.
CLINICAL INFECTIOUS DISEASES (2021)
Invasive Fungal Disease Complicating Coronavirus Disease 2019: When It Rains, It Spores
Martin Hoenigl
CLINICAL INFECTIOUS DISEASES (2021)
Investigational Agents for the Treatment of Resistant Yeasts and Molds
Garret T. Seiler et al.
CURRENT FUNGAL INFECTION REPORTS (2021)
Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumocystis Pneumonia
Lynn Miesel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
In vitro activity of the novel antifungal olorofim against dermatophytes and opportunistic moulds including Penicillium and Talaromyces species
Ashutosh Singh et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent
Lindsey Cass et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2021)
Potency of Olorofim (F901318) Compared to Contemporary Antifungal Agents against Clinical Aspergillus fumigatus Isolates and Review of Azole Resistance Phenotype and Genotype Epidemiology in China
Huilin Su et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology
Martin Hoenigl et al.
LANCET INFECTIOUS DISEASES (2021)
Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata
Ahmed Gamal et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2021)
Manogepix, the Active Moiety of the Investigational Agent Fosmanogepix, Demonstrates In Vitro Activity against Members of the Fusarium oxysporum and Fusarium solani Species Complexes
Hamid Badali et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Antifungal Susceptibility Profiles of Olorofim (Formerly F901318) and Currently Available Systemic Antifungals against Mold and Yeast Phases of Talaromyces marneffei
Jing Zhang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
In vitro activity of olorofim against clinical isolates of the Fusarium oxysporum and Fusarium solani species complexes
Hamid Badali et al.
MYCOSES (2021)
A High Rate of Recurrent Vulvovaginal Candidiasis and Therapeutic Failure of Azole Derivatives Among Iranian Women
Amir Arastehfar et al.
FRONTIERS IN MICROBIOLOGY (2021)
In Vitro Activity of Ibrexafungerp against a Collection of Clinical Isolates of Aspergillus, Including Cryptic Species and Cyp51A Mutants, Using EUCAST and CLSI Methodologies
Olga Rivero-Menendez et al.
JOURNAL OF FUNGI (2021)
Environmental Clonal Spread of Azole-Resistant Candida parapsilosis with Erg11-Y132F Mutation Causing a Large Candidemia Outbreak in a Brazilian Cancer Referral Center
Danilo Y. Thomaz et al.
JOURNAL OF FUNGI (2021)
In Vitro Activity of Novel Antifungal Olorofim against Filamentous Fungi and Comparison to Eight Other Antifungal Agents
Ourania Georgacopoulos et al.
JOURNAL OF FUNGI (2021)
Multidrug-resistant Trichosporon species: underestimated fungal pathogens posing imminent threats in clinical settings
Amir Arastehfar et al.
CRITICAL REVIEWS IN MICROBIOLOGY (2021)
Diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients: results from a European confederation of medical mycology registry
Juergen Prattes et al.
INTENSIVE CARE MEDICINE (2021)
COVID-19 associated pulmonary aspergillosis: regional variation in incidence and diagnostic challenges
Juergen Prattes et al.
INTENSIVE CARE MEDICINE (2021)
ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries
Shivaprakash M. Rudramurthy et al.
MYCOSES (2021)
Aspergillus fumigatus and aspergillosis: From basics to clinics
A. Arastehfar et al.
STUDIES IN MYCOLOGY (2021)
Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018-2019)
Michael A. Pfaller et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2021)
Genetically related micafungin-resistant Candida parapsilosis blood isolates harbouring novel mutation R658G in hotspot 1 of Fks1p: a new challenge?
Amir Arastehfar et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Ibrexafungerp: A novel oral glucan synthase inhibitor
M. R. Davis et al.
MEDICAL MYCOLOGY (2020)
Rezafungin In Vitro Activity against Contemporary Nordic Clinical Candida Isolates and Candida auris Determined by the EUCAST Reference Method
Marie Helleberg et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis
Sondus Alkhazraji et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
In Vitro Activity of Ibrexafungerp (SCY-078) against Candida auris Isolates as Determined by EUCAST Methodology and Comparison with Activity against C. albicans and C. glabrata and with the Activities of Six Comparator Agents
Maiken Cavling Arendrup et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope® registry 2008-2019
J. D. Jenks et al.
CLINICAL MICROBIOLOGY AND INFECTION (2020)
Pan-resistant Candida auris isolates from the outbreak in New York are susceptible to ibrexafungerp (a glucan synthase inhibitor)
Y. C. Zhu et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim
Wilson Lim et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Antifungal susceptibility, genotyping, resistance mechanism, and clinical profile of Candida tropicalis blood isolates
Amir Arastehfar et al.
MEDICAL MYCOLOGY (2020)
Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: Analysis of patients in the FungiScope® registry
Jeffrey D. Jenks et al.
MYCOSES (2020)
Drug resistance and tolerance in fungi
Judith Berman et al.
NATURE REVIEWS MICROBIOLOGY (2020)
Hope on the Horizon: Novel Fungal Treatments in Development
Adriana M. Rauseo et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Manogepix (APX001A) Displays Potent In Vitro Activity against Human Pathogenic Yeast, but with an Unexpected Correlation to Fluconazole MICs
Maiken Cavling Arendrup et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-D-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis
Vidmantas Petraitis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus
Teclegiorgis Gebremariam et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Lack of Effect of Rezafungin on QT/QTc Interval in Healthy Subjects
Shawn Flanagan et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2020)
Mutations in TAC1B: a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris
Jeffrey M. Rybak et al.
MBIO (2020)
Low level of antifungal resistance of Candida glabrata blood isolates in Turkey: Fluconazole minimum inhibitory concentration and FKS mutations can predict therapeutic failure
Amir Arastehfar et al.
MYCOSES (2020)
In Vitro Activity of Manogepix (APX001A) and Comparators against Contemporary Molds: MEC Comparison and Preliminary Experience with Colorimetric MIC Determination
Karin Meinike Jorgensen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Manogepix (APX001A) In Vitro Activity against Candida auris: Head-to-Head Comparison of EUCAST and CLSI MICs
Maiken Cavling Arendrup et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
First Report of Candidemia Clonal Outbreak Caused by Emerging Fluconazole-Resistant Candida parapsilosis Isolates Harboring Y132F and/or Y132F+K143R in Turkey
Amir Arastehfar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Expandable and reversible copy number amplification drives rapid adaptation to antifungal drugs
Robert T. Todd et al.
ELIFE (2020)
In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus
Lisa Kirchhoff et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Review of the Novel Investigational Antifungal Olorofim
Nathan P. Wiederhold
JOURNAL OF FUNGI (2020)
COVID-19 Associated Pulmonary Aspergillosis (CAPA)-From Immunology to Treatment
Amir Arastehfar et al.
JOURNAL OF FUNGI (2020)
Needles in a haystack: Extremely rare invasive fungal infections reported in FungiScope®-Global Registry for Emerging Fungal Infections
Jon Salmanton-Garcia et al.
JOURNAL OF INFECTION (2020)
In Vitro Activity of Manogepix against Multidrug-Resistant and Panresistant Candida auris from the New York Outbreak
YanChun Zhu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies
Olga Rivero-Menendez et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Recent Increase in the Prevalence of Fluconazole-Non-susceptible Candida tropicalis Blood Isolates in Turkey: Clinical Implication of Azole-Non-susceptible and Fluconazole Tolerant Phenotypes and Genotyping
Amir Arastehfar et al.
FRONTIERS IN MICROBIOLOGY (2020)
Diagnosis of Breakthrough Fungal Infections in the Clinical Mycology Laboratory: An ECMM Consensus Statement
Jeffrey D. Jenks et al.
JOURNAL OF FUNGI (2020)
The Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens
Amir Arastehfar et al.
JOURNAL OF FUNGI (2020)
Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections
Karen Joy Shaw et al.
JOURNAL OF FUNGI (2020)
Oral ibrexafungerp efficacy and safety in the treatment of vulvovaginal candidiasis: A phase 3, randomized, blinded, study vs. placebo (VANISH-303)
J.R. Schwebke et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2020)
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance
Philipp Koehler et al.
LANCET INFECTIOUS DISEASES (2020)
Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium
Amir Arastehfar et al.
ANTIBIOTICS-BASEL (2020)
Rezafungin-Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins
Guillermo Garcia-Effron
JOURNAL OF FUNGI (2020)
Extrapolating Antifungal Animal Data to Humans-Is It Reliable?
Victoria M. Stevens et al.
CURRENT FUNGAL INFECTION REPORTS (2020)
The Evolution of Azole Resistance in Candida albicans Sterol 14α-Demethylase (CYP51) through Incremental Amino Acid Substitutions
Andrew G. Warrilow et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
A Novel 1,3-Beta-D-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis
E. L. Larkin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an In Vivo Model of Invasive Pulmonary Aspergillosis
Miao Zhao et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
No Relevant Pharmacokinetic (PK) Interaction between Rezafungin and Nine Probe Drugs: Results from a Drug-Drug Interaction (DDI) Study
Voon Ong et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
In vitro activity of APX001A against rare moulds using EUCAST and CLSI methodologies
Olga Rivero-Menendez et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
In vitro activity of olorofim (F901318) against clinical isolates of cryptic species of Aspergillus by EUCAST and CLSI methodologies
Olga Rivero-Menendez et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
AtrR Is an Essential Determinant of Azole Resistance in Aspergillus fumigatus
Sanjoy Paul et al.
MBIO (2019)
In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017
M. A. Pfaller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis
Andrej Spec et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Stress-Induced Changes in the Lipid Microenvironment of β-(1,3)-D-Glucan Synthase Cause Clinically Important Echinocandin Resistance in Aspergillus fumigatus
Shruthi Satish et al.
MBIO (2019)
Antifungal synergy of a topical triazole, PC945, with a systemic triazole against respiratory Aspergillus fumigatus infection
Thomas Colley et al.
SCIENTIFIC REPORTS (2019)
Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis
Nathan P. Wiederhold et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus
Nathan P. Wiederhold et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations
Natalie S. Nunnally et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Activity of a Novel 1,3-Beta-D-Glucan Synthase Inhibitor, Ibrexafungerp (Formerly SCY-078), against Candida glabrata
M. Ghannoum et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae
Zoltan Toth et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis
Teclegiorgis Gebremariam et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
APX001 and Other Gwt1 Inhibitor Prodrugs Are Effective in Experimental Coccidioides immitis Pneumonia
Suganya Viriyakosol et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
SCY-078, a Novel Fungicidal Agent, Demonstrates Distribution to Tissues Associated with Fungal Infections during Mass Balance Studies with Intravenous and Oral [14C] SCY-078 in Albino and Pigmented Rats
Stephen Wring et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
726. APX001 (Fosmanogepix) Is Effective in an Immunosuppressed Mouse Model of Rhizopus oryzae Infection
Teklegiorgis Gebremariam et al.
Open Forum Infectious Diseases (2019)
A phase 2b, dose-selection study evaluating the efficacy and safety of oral ibrexafungerp vs fluconazole in vulvovaginal candidiasis (DOVE)
D. Angulo et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2019)
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
Oliver A. Cornely et al.
LANCET INFECTIOUS DISEASES (2019)
CD101 Topical Compared With Oral Fluconazole for Acute Vulvovaginal Candidiasis: A Randomized Controlled Trial
Paul Nyirjesy et al.
JOURNAL OF LOWER GENITAL TRACT DISEASE (2019)
Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy
Lynn Miesel et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2019)
Clinical Pharmacokinetics and Drug-Drug Interaction Potential for Coadministered SCY-078, an Oral Fungicidal Glucan Synthase Inhibitor, and Tacrolimus
Stephen Wring et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2019)
Update from a 12-Year Nationwide Fungemia Surveillance: Increasing Intrinsic and Acquired Resistance Causes Concern
K. M. T. Astvad et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2018)
Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus
Clara E. Negri et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
The Orotomide Olorofim Is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis
Nathan P. Wiederhold et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris
Milena Kordalewska et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model
Miao Zhao et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In vitro and in vivo Evaluation of APX001A/APX001 and other Gwt1 inhibitors against Cryptococcus
Karen Joy Shaw et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Significantly Improved Pharmacokinetics Enhances In Vivo Efficacy of APX001 against Echinocandin- and Multidrug-Resistant Candida Isolates in a Mouse Model of Invasive Candidiasis
Yanan Zhao et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris
Christopher L. Hager et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis
M. Ghannoum et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method
M. C. Arendrup et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species
Nathan P. Wiederhold et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance
Anuradha Chowdhary et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azole-resistance. A nationwide survey and rationale for the DB-MSG 002 study protocol
Alexander F. A. D. Schauwvlieghe et al.
MYCOSES (2018)
Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia
Alexander Rosenberg et al.
NATURE COMMUNICATIONS (2018)
Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy
Jeffrey D. Jenks et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Contributions of yap1 Mutation and Subsequent atrF Upregulation to Voriconazole Resistance in Aspergillus flavus
Yuuta Ukai et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Candida albicans Zn Cluster Transcription Factors Tac1 and Znc1 Are Activated by Farnesol To Upregulate a Transcriptional Program Including the Multidrug Efflux Pump CDR1
Zhongle Liu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Reliable and Easy-To-Use Liquid Chromatography-Tandem Mass Spectrometry Assay for Quantification of Olorofim (F901318), a Novel Antifungal Drug, in Human Plasma and Serum
Carsten Mueller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Implications of the EUCAST Trailing Phenomenon in Candida tropicalis for the In Vivo Susceptibility in Invertebrate and Murine Models
K. M. T. Astvad et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
APX001A In Vitro Activity against Contemporary Blood Isolates and Candida auris Determined by the EUCAST Reference Method
Maiken Cavling Arendrup et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Rare mould infections caused by Mucorales, Lomentospora prolificans and Fusarium, in San Diego, CA: the role of antifungal combination therapy
Jeffrey D. Jenks et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
SCY-078, a novel IV/oral triterpenoid anti-fungal treatment in development for vulvovaginal candidiasis and other severe invasive fungal infections, is not embryo/feto-toxic
C. Carruthers et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2018)
Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design
Alexander J. Lepak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Structure-Activity Relationships of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble Echinocandin with Distinctive Pharmacokinetic Properties
Kenneth D. James et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults
Taylor Sandison et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program
Michael A. Pfaller et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates
J. B. Buil et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic Candida spp.
Laura Judith Marcos-Zambrano et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Dihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificans
Nathan P. Wiederhold et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
The global problem of antifungal resistance: prevalence, mechanisms, and management
David S. Perlin et al.
LANCET INFECTIOUS DISEASES (2017)
A Novel Zn2-Cys6 Transcription Factor AtrR Plays a Key Role in an Azole Resistance Mechanism of Aspergillus fumigatus by Coregulating cyp51A and cdr1B Expressions
Daisuke Hagiwara et al.
PLOS PATHOGENS (2017)
First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects
Michael R Hodges et al.
Open Forum Infectious Diseases (2017)
APX001A Protects Immunosuppressed Mice from Rhizopus delemar Infection
Teclegiorgis Gebremariam et al.
Open Forum Infectious Diseases (2017)
Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability
Michael R Hodges et al.
Open Forum Infectious Diseases (2017)
A multicenter, randomized, evaluator blinded, active-controlled study to evaluate the safety and efficacy of oral SCY-078 vs. oral fluconazole in 96 subjects with moderate to severe vulvovaginal candidiasis
S. Helou et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2017)
Emergence of Echinocandin Resistance Due to a Point Mutation in the fks1 Gene of Aspergillus fumigatus in a Patient with Chronic Pulmonary Aspergillosis
Cristina Jimenez-Ortigosa et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species
Wiley A. Schell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In Vivo Biomarker Analysis of the Effects of Intranasally Dosed PC945, a Novel Antifungal Triazole, on Aspergillus fumigatus Infection in Immunocompromised Mice
Genki Kimura et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
De Novo Acquisition of Resistance to SCY-078 in Candida glabrata Involves FKS Mutations That both Overlap and Are Distinct from Those Conferring Echinocandin Resistance
Cristina Jimenez-Ortigosa et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species
Michael A. Pfaller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In Vitro and In Vivo Antifungal Profile of a Novel and Long-Acting Inhaled Azole, PC945, on Aspergillus fumigatus Infection
Thomas Colley et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis
Stephen A. Wring et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin
Voon Ong et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species
Jeffrey B. Locke et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Aspergillus fumigatus Intrinsic Fluconazole Resistance Is Due to the Naturally Occurring T301I Substitution in Cyp51Ap
Florencia Leonardelli et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates
Michael A. Pfaller et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
Johan A. Maertens et al.
LANCET (2016)
F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
Jason D. Oliver et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Sterol Biosynthesis and Azole Tolerance Is Governed by the Opposing Actions of SrbA and the CCAAT Binding Complex
Fabio Gsaller et al.
PLOS PATHOGENS (2016)
Upregulation of the Adhesin Gene EPA1 Mediated by PDR1 in Candida glabrata Leads to Enhanced Host Colonization
Luis A. Vale-Silva et al.
MSPHERE (2016)
Antifungal Activities of SCY-078 (MK-3118) and Standard Antifungal Agents against Clinical Non-Aspergillus Mold Isolates
Frederic Lamoth et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungi Cryptococcus gattii and Cryptococcus neoformans
Luiz R. Basso et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Structural mechanism of ergosterol regulation by fungal sterol transcription factor Upc2
Huiseon Yang et al.
NATURE COMMUNICATIONS (2015)
The Investigational Agent E1210 Is Effective in Treatment of Experimental Invasive Candidiasis Caused by Resistant Candida albicans
Nathan P. Wiederhold et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Enfumafungin Derivative MK-3118 Shows Increased In Vitro Potency against Clinical Echinocandin-Resistant Candida Species and Aspergillus Species Isolates
Cristina Jimenez-Ortigosa et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Positions and Numbers of FKS Mutations in Candida albicans Selectively Influence In Vitro and In Vivo Susceptibilities to Echinocandin Treatment
M. Lackner et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Role of FKS Mutations in Candida glabrata: MIC Values, Echinocandin Resistance, and Multidrug Resistance
Cau D. Pham et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
ChIP-seq and In Vivo Transcriptome Analyses of the Aspergillus fumigatus SREBP SrbA Reveals a New Regulator of the Fungal Hypoxia Response and Virulence
Dawoon Chung et al.
PLOS PATHOGENS (2014)
In Vitro Activity of a New Oral Glucan Synthase Inhibitor (MK-3118) Tested against Aspergillus spp. by CLSI and EUCAST Broth Microdilution Methods
Michael A. Pfaller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Population-Based Survey of Filamentous Fungi and Antifungal Resistance in Spain (FILPOP Study)
A. Alastruey-Izquierdo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Gain-of-Function Mutations in PDR1, a Regulator of Antifungal Drug Resistance in Candida glabrata, Control Adherence to Host Cells
Luis Vale-Silva et al.
INFECTION AND IMMUNITY (2013)
Identification of a Cryptococcus neoformans Cytochrome P450 Lanosterol 14α-Demethylase (Erg11) Residue Critical for Differential Susceptibility between Fluconazole/Voriconazole and Itraconazole/Posaconazole
Edward Sionov et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
E1210, a New Broad-Spectrum Antifungal, Suppresses Candida albicans Hyphal Growth through Inhibition of Glycosylphosphatidylinositol Biosynthesis
Nao-aki Watanabe et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Activities of E1210 and Comparator Agents Tested by CLSI and EUCAST Broth Microdilution Methods against Fusarium and Scedosporium Species Identified Using Molecular Methods
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Discovery of a Novel Class of Orally Active Antifungal β-1,3-D-Glucan Synthase Inhibitors
Scott S. Walker et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
In Vitro Activity of a Novel Broad-Spectrum Antifungal, E1210, Tested against Aspergillus spp. Determined by CLSI and EUCAST Broth Microdilution Methods
Michael A. Pfaller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Efficacy of Oral E1210, a New Broad-Spectrum Antifungal with a Novel Mechanism of Action, in Murine Models of Candidiasis, Aspergillosis, and Fusariosis
Katsura Hata et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method
Michael A. Pfaller et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2011)
Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods
Michael A. Pfaller et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Contribution of CgPDR1-Regulated Genes in Enhanced Virulence of Azole-Resistant Candida glabrata
Selene Ferrari et al.
PLOS ONE (2011)
Cryptococcus neoformans Overcomes Stress of Azole Drugs by Formation of Disomy in Specific Multiple Chromosomes
Edward Sionov et al.
PLOS PATHOGENS (2010)
Heteroresistance to Fluconazole in Cryptococcus neoformans Is Intrinsic and Associated with Virulence
Edward Sionov et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Gene overexpression/suppression analysis of candidate virulence factors of Candida albicans
Yue Fu et al.
EUKARYOTIC CELL (2008)
Candida albicans cell wall proteins
W. LaJean Chaffin
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS (2008)
A Sterol-Regulatory Element Binding Protein Is Required for Cell Polarity, Hypoxia Adaptation, Azole Drug Resistance, and Virulence in Aspergillus fumigatus
Sven D. Willger et al.
PLOS PATHOGENS (2008)
Aneuploidy and isochromosome formation in drug-resistant Candida albicans
Anna Selmecki et al.
SCIENCE (2006)
Role of AFR1, an ABC transporter-encoding gene, in the in vivo response to fluconazole and virulence of Cryptococcus neoformans
M Sanguinetti et al.
INFECTION AND IMMUNITY (2006)
Functional and structural diversity in the Als protein family of Candida albicans
DC Sheppard et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of candida albicans ABC transporters CDR1 and CDR2
AT Coste et al.
EUKARYOTIC CELL (2004)
Medicinal genetics approach towards identifying the molecular target of a novel inhibitor of fungal cell wall assembly
K Tsukahara et al.
MOLECULAR MICROBIOLOGY (2003)
The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro
JC Bowman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates
S Arikan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
The cell wall architecture of Candida albicans wild-type cells and cell wall-defective mutants
JC Kapteyn et al.
MOLECULAR MICROBIOLOGY (2000)
分享论文
